BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24952891)

  • 1. Aberrant promoter methylation of the CHD1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis.
    Gu X; Xue JQ; Zhu X; Ye MS; Zhang WH
    Tumour Biol; 2014 Sep; 35(9):9395-404. PubMed ID: 24952891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis.
    Dai D; Dong XH; Cheng ST; Zhu G; Guo XL
    Tumour Biol; 2014 Aug; 35(8):8209-16. PubMed ID: 24850174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant promoter methylation of the vimentin gene may contribute to colorectal carcinogenesis: a meta-analysis.
    Li YW; Kong FM; Zhou JP; Dong M
    Tumour Biol; 2014 Jul; 35(7):6783-90. PubMed ID: 24729088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant promoter methylation of p15 (INK⁴b) and p16 (INK⁴a) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis.
    Wang X; Zhu YB; Cui HP; Yu TT
    Tumour Biol; 2014 Sep; 35(9):9035-43. PubMed ID: 24908414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant promoter methylation of the SFRP1 gene may contribute to colorectal carcinogenesis: a meta-analysis.
    Chen YZ; Liu D; Zhao YX; Wang HT; Gao Y; Chen Y
    Tumour Biol; 2014 Sep; 35(9):9201-10. PubMed ID: 24929326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal MGMT promoter methylation may contribute to the risk of esophageal cancer: a meta-analysis of cohort studies.
    Zhao JJ; Li HY; Wang D; Yao H; Sun DW
    Tumour Biol; 2014 Oct; 35(10):10085-93. PubMed ID: 25015189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies.
    Li YS; Xie Q; Yang DY; Zheng Y
    Mol Biol Rep; 2014 Jun; 41(6):3925-33. PubMed ID: 24566681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis.
    Li FF; Yang Y; Wang XL; Hong YY; Wang NF; Chen ZD
    Tumour Biol; 2014 Jun; 35(6):6011-20. PubMed ID: 24659425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CDH1 promoter methylation in colorectal carcinogenesis: a meta-analysis.
    Li YX; Lu Y; Li CY; Yuan P; Lin SS
    DNA Cell Biol; 2014 Jul; 33(7):455-62. PubMed ID: 24684676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis.
    Si JG; Su YY; Han YH; Chen RH
    Genet Test Mol Biomarkers; 2014 Jun; 18(6):394-402. PubMed ID: 24665911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies.
    Wang HL; Liu P; Zhou PY; Zhang Y
    Ann Hum Genet; 2014 May; 78(3):208-16. PubMed ID: 24621386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter methylation and polymorphism of E-cadherin gene may confer a risk to prostate cancer: a meta-analysis based on 22 studies.
    Chang Z; Zhou H; Liu Y
    Tumour Biol; 2014 Oct; 35(10):10503-13. PubMed ID: 25056535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between promoter methylation in the GSTP1 gene and hepatocellular carcinoma development: a meta-analysis.
    Li QF; Li QY; Gao AR; Shi QF
    Genet Mol Res; 2015 Jun; 14(2):6762-72. PubMed ID: 26125884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis.
    Wang HL; Zhang Y; Liu P; Zhou PY
    Mol Biol Rep; 2014 Jun; 41(6):3991-9. PubMed ID: 24566684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant promoter methylation of SOCS-1 gene may contribute to the pathogenesis of hepatocellular carcinoma: a meta-analysis.
    Zhao RC; Zhou J; He JY; Wei YG; Qin Y; Li B
    J BUON; 2016; 21(1):142-51. PubMed ID: 27061542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis.
    Jiang JL; Tian GL; Chen SJ; Xu LI; Wang HQ
    Exp Ther Med; 2015 Oct; 10(4):1549-1555. PubMed ID: 26622524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of CDH1 promoter polymorphism and DNA methylation in bladder carcinogenesis: a meta-analysis.
    Wang Y; Kong CZ; Zhang Z; Yang CM; Li J
    DNA Cell Biol; 2014 Apr; 33(4):205-16. PubMed ID: 24491043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.
    Yang J; Niu H; Huang Y; Yang K
    PLoS One; 2016; 11(5):e0149185. PubMed ID: 27153114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between p16 gene promoter methylation and clinicopathologic features of colorectal cancer: a meta-analysis of 27 cohort studies.
    Chen YZ; Liu D; Zhao YX; Wang HT; Gao Y; Chen Y
    DNA Cell Biol; 2014 Oct; 33(10):729-38. PubMed ID: 24979649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies.
    Fang C; Wei XM; Zeng XT; Wang FB; Weng H; Long X
    BMC Cancer; 2015 Nov; 15():920. PubMed ID: 26585467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.